These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 16908728)

  • 1. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863).
    Gladstone DE; Peyster R; Baron E; Friedman-Urevich S; Sibony P; Melville P; Gottesman M
    Am J Ther; 2011 Jan; 18(1):23-30. PubMed ID: 19770795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L; Parigi A; Barilaro A; Repice AM; Pellicanò G; Konze A; Siracusa G; Taiuti R; Amaducci L
    Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.
    Kozák T; Havrdová E; Pit'ha J; Gregora E; Pytlík R; Maaloufová J; Marecková H; Kobylka P; Vodvárková S
    Bone Marrow Transplant; 2000 Mar; 25(5):525-31. PubMed ID: 10713630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS.
    Smith D
    J Neurol Sci; 2004 Aug; 223(1):73-9. PubMed ID: 15261565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.
    Llufriu S; Castillo J; Blanco Y; Ramió-Torrentà L; Río J; Vallès M; Lozano M; Castellà MD; Calabia J; Horga A; Graus F; Montalban X; Saiz A
    Neurology; 2009 Sep; 73(12):949-53. PubMed ID: 19770470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
    Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy.
    Gladstone DE; Prestrud AA; Brannagan TH
    J Peripher Nerv Syst; 2005 Mar; 10(1):11-6. PubMed ID: 15703014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized crossover study of bee sting therapy for multiple sclerosis.
    Wesselius T; Heersema DJ; Mostert JP; Heerings M; Admiraal-Behloul F; Talebian A; van Buchem MA; De Keyser J
    Neurology; 2005 Dec; 65(11):1764-8. PubMed ID: 16221950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
    J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].
    Pascual AM; Boscá I; Escutia M; Bernat A; Coret F; Casanova B
    Neurologia; 2008 Mar; 23(2):73-7. PubMed ID: 17641984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.